CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.
NeuropsychopharmacologyJul 7, 2026 (epub)
Wojciech Paslawski, Daniel Doyon, Carl Johan Ekman et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of psilocybin therapy on cerebrospinal fluid (CSF) biomarkers in patients with major depressive disorder. The study found that psilocybin significantly reduced levels of CSF galanin and noradrenaline, suggesting these changes may be crucial to its antidepressant effects.
Key findings
- Psilocybin therapy led to a selective reduction in CSF galanin levels.
- Noradrenaline levels in CSF were also significantly decreased following psilocybin treatment.
- These changes in co-transmitter levels may represent a key pharmacodynamic signature of psilocybin.
Why it matters
Understanding the mechanisms by which psilocybin exerts its antidepressant effects can inform treatment strategies for major depressive disorder, particularly for patients who do not respond to conventional therapies.